Salim Syed
Stock Analyst at Mizuho
(2.05)
# 2,832
Out of 4,711 analysts
76
Total ratings
34.43%
Success rate
-2.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $13.51 | +62.84% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $2.37 | +575.11% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $92.57 | +8.03% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $48.87 | +110.76% | 6 | Nov 21, 2024 | |
| BIIB Biogen | Maintains: Outperform | $251 → $207 | $146.47 | +41.33% | 15 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $86.53 | +88.37% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $11.40 | +57.89% | 4 | Aug 16, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $263.38 | -10.78% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $22.47 | +51.31% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $40.72 | +143.12% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $26.49 | +100.08% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.96 | +525.13% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.52 | +1,281.58% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $15.21 | +136.69% | 1 | Nov 16, 2022 |
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $13.51
Upside: +62.84%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $2.37
Upside: +575.11%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $92.57
Upside: +8.03%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $48.87
Upside: +110.76%
Biogen
Nov 21, 2024
Maintains: Outperform
Price Target: $251 → $207
Current: $146.47
Upside: +41.33%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $86.53
Upside: +88.37%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $11.40
Upside: +57.89%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $263.38
Upside: -10.78%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.47
Upside: +51.31%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $40.72
Upside: +143.12%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $26.49
Upside: +100.08%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.96
Upside: +525.13%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.52
Upside: +1,281.58%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $15.21
Upside: +136.69%